14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
DSGN vs CRMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DSGN carries a Unified Composite Score of 45.6/100 (HOLD) at $9.84 (N/M Forward P/E, 0.0% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.67 (29.5x Forward P/E, 41.0% operating margin).
Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. DSGN 45.6/100 HOLD) and 1.22β · 103% Vol risk profile, whereas DSGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.2); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $670.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CRMD Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $370.6M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment46.4% of Rev ($469M)
90D Engineering Disclosures0 Published
Investor FAQ DSGN vs CRMD Key Questions & Quantitative Answers
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DSGN carries a Unified Composite Score of 45.6/100 (HOLD) at $9.84 (N/M Forward P/E, 0.0% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.67 (29.5x Forward P/E, 41.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. DSGN 45.6/100 HOLD) and 1.22β · 103% Vol risk profile, whereas DSGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.2); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DSGN leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), DSGN cumulative revenue shifted N/A while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($469M) (0 disclosures) for CRMD.
CRMD screens cheaper on headline valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus CRMD (15.3% ROE) capital efficiency.
In options market volatility and institutional positioning, DSGN carries 96.4% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 60% Vol realized risk). By comparison, CRMD carries 127.2% implied volatility (90th %ile, Extreme (>80th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.